irinotecan has been researched along with Bladder Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Mathew Thomas, V; Swami, U; Tripathi, N | 1 |
| Gatalica, Z; Vranic, S | 1 |
| Arndt, CA; Casey, DL; Chi, YY; Donaldson, SS; Gupta, AA; Hawkins, DS; Lautz, TB; Rodeberg, DA; Routh, JC; Tian, J; Wolden, SL; Yock, TI | 1 |
| Hasegawa, M; Hattori, S; Ide, H; Kikuchi, E; Miyajima, A; Oya, M; Yasumizu, Y | 1 |
| Chang, IH; Chi, BH; Choi, SS; Kim, KD; Kim, SU; Lee, HJ; Lee, SR | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Chen, KC; Prijovich, ZM; Roffler, SR | 1 |
| Bhattacharyya, M; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Albanes, D; Baris, D; Black, A; Burdett, L; Carrato, A; Chanock, SJ; Chatterjee, N; De Vivo, I; Diver, WR; Figueroa, JD; Fraumeni, JF; Fu, YP; Gapstur, SM; Garcia-Closas, M; Garcia-Closas, R; Hall, JL; Hunter, DJ; Hutchinson, A; Jacobs, EJ; Johnson, A; Karagas, MR; Kogevinas, M; Liu, L; Lloreta, J; Malats, N; Myers, T; Porter-Gill, P; Prokunina-Olsson, L; Purdue, MP; Rothman, N; Schned, A; Schwenn, M; Serra, C; Silverman, DT; Tang, W; Tardón, A; Thun, M; Virtamo, J | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Hasegawa, Y; Hayashi, N; Kato, Y; Wakita, T | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Goi, T; Hirono, Y; Iida, A; Ishida, M; Katayama, K; Maeda, H; Murakami, M; Obata, S; Yamaguchi, A | 1 |
| Funahashi, M; Murayama, T; Yamada, T | 1 |
| Mohile, SG; Petrylak, DP; Schleicher, L | 1 |
| Dillahey, D; El-Galley, RE; Gomaa, A; Graham, SD; Keane, TE; McGuire, WP; Petros, JA; Sun, C | 1 |
| Misset, JL | 1 |
3 review(s) available for irinotecan and Bladder Cancer
| Article | Year |
|---|---|
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Diarrhea; Humans; Immunoconjugates; Irinotecan; Neutropenia; Urinary Bladder Neoplasms | 2022 |
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers; Humans; Immunoconjugates; Irinotecan; Urinary Bladder Neoplasms | 2022 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
2 trial(s) available for irinotecan and Bladder Cancer
| Article | Year |
|---|---|
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
12 other study(ies) available for irinotecan and Bladder Cancer
| Article | Year |
|---|---|
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Extremities; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Irinotecan; Male; Radiotherapy; Randomized Controlled Trials as Topic; Retroperitoneal Neoplasms; Rhabdomyosarcoma; Risk; Treatment Failure; Urinary Bladder Neoplasms; Vincristine; Young Adult | 2019 |
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Oxonic Acid; RNA Interference; RNA, Small Interfering; Tegafur; Thymidylate Synthase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Irinotecan; Mice; Neoplasm Transplantation; Neural Stem Cells; Prodrugs; Urinary Bladder Neoplasms | 2016 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Proliferation; Female; Flow Cytometry; Glucuronates; Glucuronidase; Humans; Irinotecan; Mice; Mice, SCID; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2009 |
Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.
Topics: Camptothecin; Carcinogens; Case-Control Studies; Chromosome Mapping; Genetic Predisposition to Disease; Genome-Wide Association Study; Glucuronosyltransferase; Humans; Irinotecan; Liver; Phenotype; Polymorphism, Single Nucleotide; Protein Isoforms; Risk Factors; RNA, Messenger; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
[A young patient with invasive small cell carcinoma of the urinary bladder: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2005 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
[A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Aorta; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Quality of Life; Remission Induction; Sigmoid Neoplasms; Splenic Neoplasms; Urinary Bladder Neoplasms | 2007 |
[Small cell carcinoma of the urinary bladder treated with neo-adjuvant cp chemotherapy (CPT-11 and CDDP): a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Male; Urinary Bladder Neoplasms | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystectomy; Diagnosis, Differential; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Neoplasm Recurrence, Local; Pelvic Neoplasms; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2008 |
Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Staging; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1998 |